StageZero Life Sciences Ltd. (OTCMKTS:SZLSF – Get Rating) saw a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,400 shares, an increase of 45.5% from the January 15th total of 4,400 shares. Based on an average daily trading volume, of 4,400 shares, the days-to-cover ratio is currently 1.5 days.
StageZero Life Sciences Stock Performance
SZLSF stock traded up $0.00 during midday trading on Monday, hitting $0.05. 1,000 shares of the stock traded hands, compared to its average volume of 6,350. The firm has a market cap of $5.60 million, a P/E ratio of -0.76 and a beta of 0.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.08 and a quick ratio of 0.04. The stock's fifty day simple moving average is $0.05 and its 200-day simple moving average is $0.06. StageZero Life Sciences has a 1-year low of $0.04 and a 1-year high of $0.20.
Get
StageZero Life Sciences alerts:
StageZero Life Sciences Company Profile
(Get Rating)
StageZero Life Sciences Ltd. engages in the development and commercialization of proprietary molecular diagnostic tests for detection of diseases and for personalized health management, with a focus on cancer-related indications. Its products includes Sentinel Principle, and ColonSentry. The company was founded by Choong-Chin Liew and K.
Featured Stories
- Get a free copy of the StockNews.com research report on StageZero Life Sciences (SZLSF)
- Should Medtronic's Recent Colibri Patent Controversy Concern You?
- Checkpoint Software Helps Cyber Security Stocks Bottom
- Under Armour Stock, Gap and Crap, Here's Why
- Is Chevron Positioned To Take Energy Sector Leadership?
- What Does the Consumer Price Index Measure?
Receive News & Ratings for StageZero Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StageZero Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
StageZero生命科學有限公司(OTCMKTS：SZLSF-GET Rating)在1月份看到空頭股數的顯著增長。截至1月31日，空頭股數共有6400股，比1月15日的4400股增加了45.5%。以日均成交量4,400股計算，目前天數與回補比率為1.5天。
StageZero生命科學類股表現
週一午盤，SZLSF股價上漲0.00美元，觸及0.05美元。該股有1000股易手，而其平均成交量為6350股。該公司市值為560萬美元，本益比為-0.76，貝塔係數為0.90。該公司的債務權益比為0.44，流動比率為0.08，速動比率為0.04。該股的50日簡單移動均線為0.05美元，200日簡單移動均線為0.06美元。StageZero生命科學的一年低點為0.04美元，一年高位為0.20美元。
到達
StageZero生命科學警報：
StageZero生命科學公司簡介
(獲取評級)
StageZero生命科學有限公司致力於專利分子診斷測試的開發和商業化，用於檢測疾病和個性化健康管理，重點是癌症相關適應症。其產品包括哨兵原理和科隆哨兵。該公司是由劉忠欽和K。
專題報道
- 免費獲取StockNews.com關於StageZero生命科學(SZLSF)的研究報告
- 美敦力最近的Colibri專利爭議是否應該引起您的關注？
- Checkpoint軟體幫助網路安全類股觸底
- 在裝甲庫存、缺口和垃圾下，這就是為什麼
- 雪佛龍做好了引領能源行業的準備嗎？
- 消費者物價指數衡量的是什麼？
接受StageZero生命科學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對StageZero生命科學和相關公司的最新新聞和分析師評級的每日簡要摘要。
